Welcome to our dedicated page for CLOROX CO /DE/ SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOROX CO /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOROX CO /DE/'s regulatory disclosures and financial reporting.
Hyder Chris T reported acquisition or exercise transactions in this Form 4 filing.
Clorox executive Chris T. Hyder received a stock grant that increases his direct holdings. He was awarded 42,118 shares of Clorox common stock on June 17, 2026, as a grant or award valued at $94.97 per share. After this grant, he directly holds 77,087 shares. A related footnote states that these Restricted Stock Units will vest in full on June 17, 2029, three years after the grant date.
The Clorox Company announced a streamlined operating structure and key leadership changes. Chris Hyder was appointed executive vice president and chief operating officer, effective June 17, 2026, consolidating leadership of all business units under a single executive to drive end-to-end execution.
In connection with his promotion, Hyder’s base salary will increase to $800,000, and his short-term incentive target will rise from 90% to 100% of salary. He will also receive $4,000,000 in restricted stock units on June 17, 2026, vesting after three years.
Nina Barton, previously executive vice president and group president – Care & Connection, was named executive vice president and chief growth & strategy officer, effective June 17, 2026, with responsibility for innovation, strategy, portfolio shaping and commercial functions. The company highlighted these changes as part of a simplified structure intended to improve execution and accelerate growth, while the board continues a comprehensive search for a new CEO.
The Clorox Company announced that Chair and CEO Linda Rendle has asked the board to begin a comprehensive CEO search as she plans to step down for health reasons. She will remain in her roles while the search is conducted and until a new CEO is appointed.
Rendle will then serve in an advisory position for a period to support business performance and a smooth leadership transition. An independent board committee, supported by an external executive search firm, will lead the process. Rendle and CFO Luc Bellet also plan to speak at the dbAccess Global Consumer Conference on June 3 in Paris.
The Clorox Company entered into an underwriting agreement for a registered public offering of new senior notes. The company sold $550,000,000 of 4.700% Senior Notes due 2031, $400,000,000 of 4.950% Senior Notes due 2033, and $550,000,000 of 5.250% Senior Notes due 2036. The offering closed on May 11, 2026, under an existing Indenture dated May 11, 2022, with U.S. Bank Trust Company, National Association, as trustee. Legal validity of the securities is supported by an opinion from Cleary Gottlieb Steen & Hamilton LLP.
The Clorox Company is offering three series of senior unsecured notes: $550,000,000 4.700% due May 15, 2031, $400,000,000 4.950% due May 15, 2033 and $550,000,000 5.250% due May 15, 2036. Interest accrues from May 11, 2026 and is payable semi-annually on May 15 and November 15, beginning November 15, 2026.
Net proceeds are intended to repay borrowings under a $1,250,000,000 Delayed Draw Term Facility and to pay down certain commercial paper; any remainder will be used for general corporate purposes. The notes are senior unsecured, will rank equally with other senior unsecured indebtedness and are not listed on an exchange.
The Clorox Company is offering multiple series of senior unsecured notes to raise proceeds intended to repay outstanding borrowings, including an aggregate $1,250,000,000 draw on its Delayed Draw Term Facility and to pay down commercial paper, with any remainder for general corporate purposes; the prospectus supplement is subject to completion.
The notes will be senior unsecured obligations, issued in denominations of $2,000, bear semi-annual interest, include optional make-whole redemption features and a Change of Control repurchase at 101% upon certain rating and control events. The offering involves conflicts of interest under FINRA Rule 5121 because certain underwriters are lenders or commercial paper holders.
Clorox director Pierre R. Breber, through a trust, made an open-market purchase of 5,000 shares of Common Stock at a weighted average price of about $85.82 per share. Following this transaction, the trust’s indirect holdings increased to 18,000 Clorox shares.
The shares were bought in multiple trades within a price range from $85.19 to $86.01, according to the filing footnote.
The Clorox Company filed a shelf registration on April 30, 2026 to offer senior debt securities from time to time under a registration statement on Form S-3, permitting issuance in one or more series for an indeterminate aggregate principal amount. The prospectus describes general terms, the Indenture dated May 11, 2022, distribution methods and customary covenants, including limits on secured debt and sale-leaseback transactions.
The prospectus will be supplemented with series-specific terms (principal amount, maturity, interest rate, denominations, and plan of distribution) in prospectus supplements; uses of net proceeds will be stated in those supplements.
The Clorox Company reported quarterly net sales of $1.67 billion, essentially flat year over year, while nine‑month sales fell 7% to $4.77 billion as prior‑year ERP‑related shipments were lapped. Quarterly diluted EPS rose to $1.54, but nine‑month diluted EPS declined 10% to $3.47.
Gross margin compressed to 43.2% this quarter and 42.7% year‑to‑date, mainly from higher manufacturing and logistics costs and mix, partly offset by cost savings. Selling and administrative expenses and advertising both declined in dollars and as a percentage of sales, reflecting lower transformation and incentive costs.
Clorox paid $476 million to acquire Procter & Gamble’s 20% Glad venture interest and closed the roughly $2.25 billion acquisition of GOJO shortly after quarter end. To support these transactions, notes and loans payable increased to $1.59 billion, while cash and cash equivalents rose to $1.19 billion, and the company added new committed credit facilities. The long‑running ERP and digital transformation program, totaling about $580 million, was completed in the quarter.
The Clorox Company reported mixed third-quarter fiscal 2026 results. Net sales were $1.67 billion, essentially flat year over year, while organic sales decreased 1%. Gross margin fell 140 basis points to 43.2% as higher manufacturing and logistics costs and unfavorable mix more than offset cost savings.
Diluted EPS rose 3% to $1.54, and adjusted EPS grew 13% to $1.64, helped by cost savings, lower advertising and lower selling and administrative expenses. Year-to-date net cash provided by operations was $282 million, down 59% from $687 million, mainly due to a Glad joint venture termination payment.
The company completed its acquisition of GOJO Industries on April 1, adding the Purell brand and related health and hygiene products. Clorox cut its full-year 2026 outlook, now expecting net sales to decline about 6% and organic sales to decrease about 9%. Fiscal 2026 diluted EPS is projected between $4.78 and $4.98, a 24% to 27% decline, while adjusted EPS is guided to $5.45 to $5.65, down 27% to 29%, reflecting ERP-related shipment timing, GOJO integration costs and ongoing digital investments.